- cafead Apr 13, 2022 at 05:52: PM
via Turning Point Therapeutics shared a Phase I/II update for its lead drug candidate repotrectinib, but investors said they were expecting slightly better.
In 71 total TKI-naive patients, the confirmed objective response rate (cORR) to repotrectinib, also known as TPX-0005, was 79%, down from an earlier report of a 91% ORR in 22 patients. In addition, four patients achieved complete response, Turning Point said in a press release.
article source
In 71 total TKI-naive patients, the confirmed objective response rate (cORR) to repotrectinib, also known as TPX-0005, was 79%, down from an earlier report of a 91% ORR in 22 patients. In addition, four patients achieved complete response, Turning Point said in a press release.
article source